ArticleFrontiers in surgery2026
Effect of preoperative tranexamic acid on hidden blood loss and C-reactive protein in patients undergoing Delta-channel endoscopic lumbar discectomy: a retrospective case-control study.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The minimally invasive Delta-channel interlaminar endoscopic discectomy has been increasingly applied in clinical practice. However, the impact of tranexamic acid (TXA) on hidden blood loss (HBL) and C-reactive protein (CRP) levels in patients undergoing this procedure remains unclear. Accordingly, the present study is designed to investigate the impact of intravenous TXA on postoperative HBL and CRP levels in patients with lumbar disc herniation (LDH) treated via Delta-channel interlaminar endoscopic discectomy. Methods: A retrospective analysis was conducted on clinical data of 69 LDH patients who underwent Delta-channel interlaminar endoscopic discectomy between January 2023 and December 2024. Patients were divided into two groups. Of these, 25 patients who received intravenous infusion of 1 g TXA 15 min prior to skin incision were assigned to the observation group, whereas 44 patients who did not receive TXA were allocated to the control group. The following parameters were recorded as observation indicators, including operation time, intraoperative blood loss (IBL), HBL, postoperative activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen (FIB), platelet count (PLT), D-dimer, CRP, hemoglobin (HB), red blood cell count (RBC), hematocrit (HCT), incision healing status, and the incidence of lower extremity deep vein thrombosis (DVT). Results: All surgeries were completed successfully, with all incisions achieving primary healing and no DVT events reported in either group. The HBL in the observation group was significantly lower than that in the control group, with a statistically significant difference ( Conclusion: When treating LDH with Delta-channel interlaminar endoscopic discectomy, preoperative intravenous administration of TXA can effectively reduce HBL and serves as a protective factor against HBL. Meanwhile, it does not significantly affect postoperative CRP levels, indicating that it does not interfere with the clinical evaluation of postoperative inflammatory responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.